Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf Natural ...
April 27 2017 - 8:00AM
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, today announced that it will host a Focus Session
entitled “Off-the-Shelf Natural Killer Cell Cancer Immunotherapy”
to kick-off the upcoming 2017 Annual Meeting of the International
Society for Stem Cell Research (ISSCR) on Wednesday, June 14, 2017
from 9:00 a.m. to 12:00 p.m. ET in Boston, Massachusetts.
The Focus Session will feature renowned guest speakers and
provide an in-depth overview of the Company’s off-the-shelf natural
killer (NK) cell product pipeline emerging from its
industry-leading induced pluripotent stem cell (iPSC)
platform. Fate Therapeutics and its collaborators are
developing first-of-kind activated and tumor-targeted NK- and
T-cell immunotherapies derived from master engineered pluripotent
cell lines for the treatment of cancer. The Company has
previously shown that its hnCD16-NK cell product candidate, derived
from a master engineered pluripotent cell line expressing a novel
high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, exhibits
superior anti-tumor activity in preclinical studies compared to
conventional NK cells sourced from peripheral blood and cord
blood. In addition, the Company and its collaborators are
assessing in preclinical studies the anti-tumor activity of several
CAR-NK cells derived from master pluripotent cell lines engineered
with novel chimeric antigen receptors (CARs).
Speakers scheduled to participate in the session include:
- Dan S. Kaufman, M.D., Ph.D., Professor of Medicine, Division of
Regenerative Medicine, Director of Cell Therapy, University of
California, San Diego
- Karl-Johan Malmberg, M.D., Ph.D., Group Leader of Natural
Killer Cell Biology and Cell Therapy, Department of Immunology,
Oslo University Hospital
- Jeffrey S. Miller, M.D., Professor of Medicine, Deputy
Director of the Masonic Cancer Center, University of
Minnesota
- Dan Shoemaker, Ph.D., Chief Scientific Officer, Fate
Therapeutics, Inc.
- Bob Valamehr, Ph.D., Vice President, Cancer Immunotherapy,
Fate Therapeutics, Inc.
The Focus Session will be available for review on the Company’s
website at www.fatetherapeutics.com following the conclusion of the
ISSCR Annual Meeting.
About Fate Therapeutics’ iPSC PlatformThe
Company’s proprietary iPSC platform enables genetic engineering and
high-throughput single-cell isolation, selection, and
characterization of human iPSCs and supports long-term maintenance
of clonally-expanded human iPSCs as master pluripotent cell
lines. Human iPSCs possess the unique dual properties of
unlimited self-renewal and differentiation potential into all cell
types of the body. Similar to master cell lines used for the
manufacture of monoclonal antibodies, master pluripotent cell lines
can serve as a renewable cell source for the consistent and
repeated manufacture of homogeneous populations of cell products
with the potential to treat many different diseases and many
thousands of patients in an off-the-shelf manner. Fate
Therapeutics’ iPSC platform is supported by an intellectual
property portfolio of over 60 issued patents and 90 pending patent
applications.
About Fate Therapeutics, Inc.Fate
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for cancer and immune disorders. The Company’s hematopoietic cell
therapy pipeline is comprised of NK- and T-cell immuno-oncology
programs, including off-the-shelf product candidates derived from
engineered induced pluripotent cells, and immuno-regulatory
programs, including product candidates to prevent life-threatening
complications in patients undergoing hematopoietic cell
transplantation and to promote immune tolerance in patients with
autoimmune disease. Its adoptive cell therapy programs are based on
the Company’s novel ex vivo cell programming approach, which it
applies to modulate the therapeutic function and direct the fate of
immune cells. Fate Therapeutics is headquartered in San Diego, CA.
For more information, please visit www.fatetherapeutics.com.
Forward-Looking Statements
This release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the Company’s progress and
plans related to its induced pluripotent stem cell platform and its
development of off-the-shelf NK- and T-cell cancer immunotherapies
derived from master pluripotent cell lines. These and any other
forward-looking statements in this release are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that
results observed in prior studies, including preclinical studies of
its product candidates, will not be observed in ongoing or future
studies involving these product candidates, the risk that the
Company may cease or delay preclinical or clinical development
activities for any of its existing or future product candidates for
a variety of reasons, the risk that any off-the-shelf NK cell
product candidates developed by the Company may not be suitable for
therapeutic applications, and the risk that product candidates
developed by the Company may not provide the anticipated
therapeutic benefits. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the risks and uncertainties
detailed in the Company’s periodic filings with the Securities and
Exchange Commission, including but not limited to the Company’s
most recently filed periodic report, and from time to time the
Company’s other investor communications. Fate Therapeutics is
providing the information in this release as of this date and does
not undertake any obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or otherwise.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Sep 2023 to Sep 2024